A head-to-head comparison of the selective IL-23 blocker risankizumab with oral fumaric acid esters in treatment-naïve patients with moderate-to-severe psoriasis demonstrated superiority of the biologic in all assessed efficacy endpoints at week 24 .
In the Netherlands, Germany, the United Kingdom, and Ireland, fumaric acid esters are frequently used for systemic therapy of moderate-to-severe psoriasis [2-4]. A new head-to-head trial included systemic treatment-naïve adult patients with chronic moderate-to-severe plaque psoriasis of at least 6 months duration. All patients qualified for systemic therapy: they had a psoriasis area and severity index score >10, an affected body surface area of >10%, and their quality of life was severely impaired (dermatology life quality index score of >10). Patients were randomised to receive subcutaneous risankizumab 150 mg at weeks 0, 4, and 16 (n=60) or oral fumaric acid esters in increasing doses from week ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Certolizumab pegol efficacious for head and neck psoriasis Next Article
Novel selective IL-23 blocker equally effective in patients with metabolic syndrome »
Table of Contents: EADV 2019
Spotlight on Psoriasis
New Insights in Photoprotection
Rosacea – from new spectrum to new therapy
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.